Skip to main content

Table 1 Comparative baseline characteristics of the cohort at JMC, April 10–May 10, 2017

From: Abacavir versus Zidovudine-based regimens for treatment of HIV-infected children in resource limited settings: a retrospective cohort study

All n = 179ABC group (n = 87)AZT group (n = 92)P-value
Variables
SexMale42 (48.3%)39 (42.4%)0.42
Female45 (51.7%)53 (57.6%)
Age (years)< 3 years11 (12.6%)12 (13.0%)0.97
3–5 years18 (20.7%)20 (21.7%)
>  5 years58 (66.7%)60 (65.2%)
BMI (baseline)<5th centile74 (85.0%)66 (71.7%)0.03
>5th centile13 (14.9%)26 (28.3%)
Maternal HIV statusPositive78 (89.7%)83 (90.2%)0.91
Unknown9 (10.3%)9 (9.8%)
Area of residenceUrban66 (75.9%)68 (73.9%)0.76
Rural21 (24.1%)24 (26.1%)
Baseline CD4+ (Mean + SD)166.31 + 76.22178.78 + 71.120.26
WHO stageI8 (9.2%)3 (3.3%)0.08
II24 (27.6%)40 (43.5%)
III45 (51.7%)42 (45.7%)
IV10 (11.5%)7 (7.6%)
Functional statusW/A72 (82.8%)88 (95.7%)0.001
A/D12 (13.8%)0 (0.0%)
B/R3 (3.4%)4 (4.3%)
TB (treatment)Yes3 (3.4%)9 (9.8%)0.06
No84 (96.6%)83 (90.2%)
OI ProphylaxisBoth CPT and INH85 (97.7%)89 (96.7%)0.69
CPT only1 (1.1%)1 (1.1%)
Neither1 (1.1%)2 (2.2%)
Nutritional statusNormal45 (51.7%)57 (62.0%)0.17
SAM42 (48.3%)35 (38.0%)
  1. BMI body mass index, W/A working/Appropriate, A/D Ambulatory/Delay, B/R Bedridden/regression, TB Tuberculosis, CPT cotrimoxazole preventative therapy, INH Isoniazid, CD4 cluster of differentiation, SD Standard deviation, OIs opportunistic infections